326 related articles for article (PubMed ID: 27308660)
1. Complete and Sustained Off-Therapy Response to Sorafenib in Advanced Hepatocellular Carcinoma.
Maida M; Macaluso FS; Valenza F; Virdone R
J Gastrointestin Liver Dis; 2016 Jun; 25(2):253-5. PubMed ID: 27308660
[TBL] [Abstract][Full Text] [Related]
2. A complete response induced by 21-day sorafenib therapy in a patient with advanced hepatocellular carcinoma.
Hagihara A; Teranishi Y; Kawamura E; Fujii H; Iwai S; Morikawa H; Enomoto M; Tamori A; Kawada N
Intern Med; 2013; 52(14):1589-92. PubMed ID: 23857091
[TBL] [Abstract][Full Text] [Related]
3. CT imaging findings in patients with advanced hepatocellular carcinoma treated with sorafenib: Alternative response criteria (Choi, European Association for the Study of the Liver, and modified Response Evaluation Criteria in Solid Tumor (mRECIST)) versus RECIST 1.1.
Gavanier M; Ayav A; Sellal C; Orry X; Claudon M; Bronowicki JP; Laurent V
Eur J Radiol; 2016 Jan; 85(1):103-112. PubMed ID: 26724654
[TBL] [Abstract][Full Text] [Related]
4. Complete response for advanced liver cancer during sorafenib therapy: case report.
Sacco R; Bargellini I; Gianluigi G; Bertini M; Bozzi E; Altomare E; Battaglia V; Romano A; Bertoni M; Capria A; Bresci G; Bartolozzi C
BMC Gastroenterol; 2011 Jan; 11():4. PubMed ID: 21241463
[TBL] [Abstract][Full Text] [Related]
5. mRECIST response combined with sorafenib-related adverse events is superior to either criterion alone in predicting survival in HCC patients treated with TACE plus sorafenib.
Wang W; Bai W; Wang E; Zhao Y; Liu L; Yang M; Cai H; Xia D; Zhang L; Niu J; Yin Z; Zhang Z; Fan D; Xia J; Han G
Int J Cancer; 2017 Jan; 140(2):390-399. PubMed ID: 27681592
[TBL] [Abstract][Full Text] [Related]
6. Long-term outcomes of patients with advanced hepatocellular carcinoma who achieved complete remission after sorafenib therapy.
Park JG
Clin Mol Hepatol; 2015 Sep; 21(3):287-94. PubMed ID: 26527250
[TBL] [Abstract][Full Text] [Related]
7. [A case of advanced hepatocellular carcinoma successfully treated by liver resection after complete response induced by sorafenib administration].
Kim Y; Hosoda Y; Kakita N; Yamada Y; Yamasaki M; Nishino M; Okano M; Nagai K; Yasui M; Tsujinaka T
Gan To Kagaku Ryoho; 2014 Nov; 41(12):2124-6. PubMed ID: 25731444
[TBL] [Abstract][Full Text] [Related]
8. Comparison of tumor response by Response Evaluation Criteria in Solid Tumors (RECIST) and modified RECIST in patients treated with sorafenib for hepatocellular carcinoma.
Edeline J; Boucher E; Rolland Y; Vauléon E; Pracht M; Perrin C; Le Roux C; Raoul JL
Cancer; 2012 Jan; 118(1):147-56. PubMed ID: 21713764
[TBL] [Abstract][Full Text] [Related]
9. Sorafenib after resection improves the outcome of BCLC stage C hepatocellular carcinoma.
Li J; Hou Y; Cai XB; Liu B
World J Gastroenterol; 2016 Apr; 22(15):4034-40. PubMed ID: 27099447
[TBL] [Abstract][Full Text] [Related]
10. Adjuvant sorafenib for hepatocellular carcinoma after resection or ablation (STORM): a phase 3, randomised, double-blind, placebo-controlled trial.
Bruix J; Takayama T; Mazzaferro V; Chau GY; Yang J; Kudo M; Cai J; Poon RT; Han KH; Tak WY; Lee HC; Song T; Roayaie S; Bolondi L; Lee KS; Makuuchi M; Souza F; Berre MA; Meinhardt G; Llovet JM;
Lancet Oncol; 2015 Oct; 16(13):1344-54. PubMed ID: 26361969
[TBL] [Abstract][Full Text] [Related]
11. Clinical features associated with radiological response to sorafenib in unresectable hepatocellular carcinoma: a large multicenter study in Japan.
Takeda H; Nishikawa H; Osaki Y; Tsuchiya K; Joko K; Ogawa C; Taniguchi H; Orito E; Uchida Y; Izumi N;
Liver Int; 2015 May; 35(5):1581-9. PubMed ID: 24836552
[TBL] [Abstract][Full Text] [Related]
12. Evaluation of the mRECIST and α-fetoprotein ratio for stratification of the prognosis of advanced-hepatocellular-carcinoma patients treated with sorafenib.
Kawaoka T; Aikata H; Murakami E; Nakahara T; Naeshiro N; Tanaka M; Honda Y; Miyaki D; Nagaoki Y; Takaki S; Hiramatsu A; Waki K; Takahashi S; Chayama K
Oncology; 2012; 83(4):192-200. PubMed ID: 22890083
[TBL] [Abstract][Full Text] [Related]
13. Long-term complete response of advanced hepatocellular carcinoma treated with multidisciplinary therapy including reduced dose of sorafenib: case report and review of the literature.
Shinoda M; Kishida N; Itano O; Ei S; Ueno A; Kitago M; Abe Y; Hibi T; Yagi H; Masugi Y; Tanabe M; Aiura K; Sakamaoto M; Tanimoto A; Kitagawa Y
World J Surg Oncol; 2015 Apr; 13():144. PubMed ID: 25889667
[TBL] [Abstract][Full Text] [Related]
14. Alternative Response Criteria (Choi, European association for the study of the liver, and modified Response Evaluation Criteria in Solid Tumors [RECIST]) Versus RECIST 1.1 in patients with advanced hepatocellular carcinoma treated with sorafenib.
Ronot M; Bouattour M; Wassermann J; Bruno O; Dreyer C; Larroque B; Castera L; Vilgrain V; Belghiti J; Raymond E; Faivre S
Oncologist; 2014 Apr; 19(4):394-402. PubMed ID: 24652387
[TBL] [Abstract][Full Text] [Related]
15. Visceral fat area predicts survival in patients with advanced hepatocellular carcinoma treated with tyrosine kinase inhibitors.
Nault JC; Pigneur F; Nelson AC; Costentin C; Tselikas L; Katsahian S; Diao G; Laurent A; Mallat A; Duvoux C; Luciani A; Decaens T
Dig Liver Dis; 2015 Oct; 47(10):869-76. PubMed ID: 26211871
[TBL] [Abstract][Full Text] [Related]
16. Exceptional serological and radiological response to sorafenib in 2 patients with advanced hepatocellular carcinoma and chronic hepatitis C viral infection: case report and review of the literature.
Atkin C; Earwaker P; Pallan A; Shetty S; Punia P; Ma YT
BMC Gastroenterol; 2017 Feb; 17(1):30. PubMed ID: 28193171
[TBL] [Abstract][Full Text] [Related]
17. Prognostic value of perfusion CT in hepatocellular carcinoma treatment with sorafenib: comparison with mRECIST in longitudinal follow-up.
Kaufmann S; Thaiss WM; Schulze M; Bitzer M; Lauer U; Nikolaou K; Horger M
Acta Radiol; 2018 Jul; 59(7):765-772. PubMed ID: 28927298
[TBL] [Abstract][Full Text] [Related]
18. Complete pathological response induced by sorafenib for advanced hepatocellular carcinoma with multiple lung metastases and venous tumor thrombosis allowing for curative resection.
Kitajima T; Hatano E; Mitsunori Y; Taura K; Fujimoto Y; Mizumoto M; Okajima H; Kaido T; Minamiguchi S; Uemoto S
Clin J Gastroenterol; 2015 Oct; 8(5):300-5. PubMed ID: 26249525
[TBL] [Abstract][Full Text] [Related]
19. Modified response evaluation criteria in solid tumors is superior to response evaluation criteria in solid tumors for assessment of responses to sorafenib in patients with advanced hepatocellular carcinoma.
Takada J; Hidaka H; Nakazawa T; Kondo M; Numata K; Tanaka K; Matsunaga K; Okuse C; Kobayashi S; Morimoto M; Ohkawa S; Koizumi W
BMC Res Notes; 2015 Oct; 8():609. PubMed ID: 26502722
[TBL] [Abstract][Full Text] [Related]
20. Early Clinical Response after 2 Weeks of Sorafenib Therapy Predicts Outcomes and Anti-Tumor Response in Patients with Advanced Hepatocellular Carcinoma.
Kuzuya T; Ishigami M; Ishizu Y; Honda T; Hayashi K; Katano Y; Hirooka Y; Ishikawa T; Nakano I; Goto H
PLoS One; 2015; 10(9):e0138776. PubMed ID: 26421430
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
